Russia
· Delayed Price · Currency is RUB Pharmsynthez Statistics
Total Valuation
Pharmsynthez has a market cap or net worth of RUB 1.36 billion. The enterprise value is 2.05 billion.
| Market Cap | 1.36B |
| Enterprise Value | 2.05B |
Important Dates
The next estimated earnings date is Friday, September 27, 2024.
| Earnings Date | Sep 27, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Pharmsynthez has 301.01 million shares outstanding.
| Shares Outstanding | 301.01M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +2.56% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.92 |
| PB Ratio | 2.13 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -6.75 |
| EV / Sales | 5.95 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -5.65 |
Financial Position
The company has a current ratio of 0.54, with a Debt / Equity ratio of 119.59.
| Current Ratio | 0.54 |
| Quick Ratio | 0.45 |
| Debt / Equity | 119.59 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.10 |
| Interest Coverage | -2.76 |
Financial Efficiency
Return on equity (ROE) is -61.90% and return on invested capital (ROIC) is -6.08%.
| Return on Equity (ROE) | -61.90% |
| Return on Assets (ROA) | -4.65% |
| Return on Capital (ROIC) | -6.08% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.22 |
| Inventory Turnover | 4.38 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -22.59% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -22.59% |
| 50-Day Moving Average | 3.92 |
| 200-Day Moving Average | 5.11 |
| Relative Strength Index (RSI) | 63.97 |
| Average Volume (20 Days) | 9,839,310 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharmsynthez had revenue of RUB 344.17 million and -303.66 million in losses. Loss per share was -1.02.
| Revenue | 344.17M |
| Gross Profit | 74.05M |
| Operating Income | -114.14M |
| Pretax Income | -305.94M |
| Net Income | -303.66M |
| EBITDA | -97.72M |
| EBIT | -114.14M |
| Loss Per Share | -1.02 |
Balance Sheet
The company has 257.06 million in cash and 761.02 million in debt, giving a net cash position of -503.96 million or -1.67 per share.
| Cash & Cash Equivalents | 257.06M |
| Total Debt | 761.02M |
| Net Cash | -503.96M |
| Net Cash Per Share | -1.67 |
| Equity (Book Value) | 636.35M |
| Book Value Per Share | 2.11 |
| Working Capital | -475.04M |
Cash Flow
In the last 12 months, operating cash flow was -325.89 million and capital expenditures -36.69 million, giving a free cash flow of -362.58 million.
| Operating Cash Flow | -325.89M |
| Capital Expenditures | -36.69M |
| Free Cash Flow | -362.58M |
| FCF Per Share | -1.20 |
Margins
Gross margin is 21.51%, with operating and profit margins of -33.16% and -88.23%.
| Gross Margin | 21.51% |
| Operating Margin | -33.16% |
| Pretax Margin | -88.89% |
| Profit Margin | -88.23% |
| EBITDA Margin | -28.39% |
| EBIT Margin | -33.16% |
| FCF Margin | -105.35% |
Dividends & Yields
Pharmsynthez does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.60% |
| Shareholder Yield | 1.60% |
| Earnings Yield | -22.54% |
| FCF Yield | -26.74% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |